Pipeline
R&D
Careers
Contact
Overview
Daclizumab
Volociximab (M200)
Elotuzumab (HuLuc63)
PDL192
PDL241
Product |
Indication |
Pre-Clinical |
Phase 1 |
Phase 2 |
| Daclizumab | Multiple Sclerosis |  |
||
| Volociximab (M200) | Solid Tumors | |
||
| Elotuzumab (HuLuc63) | Multiple Myeloma |  |
||
| PDL192 | Solid Tumors | |
||
| PDL241 | Immunologic Diseases |  |
||
Learn More about our R&D approach..
More »
Recent Publications
Job Openings
Press Releases